Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer

Abstract

Objective:

To evaluate clinical predictors of lymph node invasion (LNI) in patients with high-risk prostate cancer undergoing radical prostatectomy (RP) with extended pelvic lymph node dissection (ePLND).

Methods:

A contemporary cohort of 116 patients, who underwent ePLND during RP, was retrospectively evaluated. Patients were classified into 3 groups including cases without LNI (group 1), with 1 to 3 positive nodes (group 2; limited LNI), and with more than 3 positive nodes (group 3; extensive LNI). The multinomial logistic regression model (multivariate analysis) evaluated the risk of LNI.

Results:

Overall, 30 patients (25.9%) had LNI, which was limited in 17 cases (14.7%) and extensive in 13 subjects (11.2%). Median prostate-specific antigen (PSA) was higher in cases with limited (11.4 ng/mL) or extensive (23.5 ng/mL) LNI than cases without (7.3 ng/mL) and the difference was significant (p <.0001). Median proportion of biopsy-positive cores was higher in limited (0.64) or extensive (0.54) LNI than cases without (0.34) and the difference was significant (p < .0001). The distribution of other factors did not show any significant difference among the groups. On multivariate analysis, only higher values of PSA significantly affected the odds of extensive LNI when compared to cases without (odds ratio, 1.054; p = .005); PSA showed a fair discrimination power (area under the curve 0.792).

Conclusion:

PSA was the only independent predictor of extensive LNI and could be an important preoperative factor for stratifying high-risk patients.

Keywords

Prostate cancer high risk lymph node invasion PSA radical prostatectomy extended pelvic lymph node dissection

Get full access to this article

View all access options for this article.

References

Gil-Vernet

JM.

Prostate cancer: anatomical and surgical considerations. Br J Urol 1996; 78: 161–168.

Heidenreich

Ohlmann

Polyakov

Anatomic extent of pelvic lymphadenectomy in patients undergoing radical prostectomy. Eur Urol 2007; 52: 29–37.

Briganti

Michael

James

et al . Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55: 1251–1265.

Breyer

Greene

Dall’Era

Davies

Kane

CJ.

Pelvic lymphadenectomy in prostate cancer. Prostate Cancer Prostatic Dis 2008; 11: 320–324.

Ploussard

Briganti

De La

Taille

et al . Pelvic lymph node dissection during robot-assisted radical prostatectomy : efficacy, and complications. a systematic review of the literature. Eur Urol 2014; 65: 7–16.

Briganti

Larcher

Abdollah

et al . Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012; 61: 480–487.

D’Amico

Whittington

Malkowicz

et al . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

Porcaro

de Luyk

Corsi

et al . Bilateral lymph node micrometastases and seminal vesicle invasion associated with same clinical predictors in localized prostate cancer. Tumori Epub 2018 Jan 29.

Moris

Van den Broeck

Tosco

et al . Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection. Front Surg 2016; 3: 65–74.

10.

Menon

Tewari

Peabody

Vattikuti Institute prostatectomy: technique. J Urol 2003; 169: 2289–2292.

11.

Walsh

Retik

Vaughan

ED.

Anatomic radical retropubic prostatectomy. In: Campbell’s Urology, 8th ed. Philadelphia: Elsevier; 2002: 3107–3129.

12.

Srigley

Humphrey

Amin

et al . Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 2009; 133: 1568–1576.

13.

Pierorazio

Walsh

Partin

Epstein

JI.

Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013; 111: 753–760.

14.

Epstein

Zelefsky

Sjoberg

et al . A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016; 69: 428–435.

15.

Suardi

Larcher

Haese

et al . Indication for extension of pelvic lymph node dissection during robot-assisted radical prostectomy: an analysis of five European institutions. Eur Urol 2014; 66: 635–643.

16.

Yuh

Artibani

Heidenreich

et al . The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol 2013; 65: 918–927.

17.

Weingartner

Ramaswamy

Bittinger

et al . Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol 1996; 156: 1969–1971.

18.

Heidenreich

Zoltan

Von Knobloch

Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastases. J Urol 2002; 167: 1681–1686.

19.

Yuh

Ruel

Mejia

Wilson

TG.

Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer. Eur Urol 2012; 61: 1004–1010.

20.

Porcaro

de Luyk

Corsi

et al . Clinical factors predicting and stratifying the risk of lymph node invasion in localized prostate cancer. Urol Int Epub 2017 Sept.

21.

Sobin

Gospodarowicz

Wittekind

TNM classification of malignant tumors. In: Sobin

Gospodarowicz

ed. International Union Against Cancer (UICC). Oxford: Wiley-Blackwell; 2009.

22.

Muck

Langesberg

Mugler

Rahnenfuhrer

Wullich B

Schafhauser

Clinical outcome of patients with lymph node-positive prostate cancer following radical prostatectomy and extended sentinel lymph node dissection. Urol Int 2015; 94: 296–306.

23.

Stamey

Yang

Hay

McNeal

Freiha

Redine

Prostate specific antigen as serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909.